The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Open accessAbstract
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the central nervous system. Although successful gene transfer has been reported in patients with hemophilia B, the large size of the factor VIII coding region has precluded improved outcomes with gene therapy in patients with hemophilia A. METHODS: We infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled sequentially into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]) and were followed through 52 weeks. RESULTS: Factor VIII activity levels remained at 3 IU or less per deciliter in the recipients of the low or intermediate dose. In the high-dose cohort, the factor VIII activity level was more than 5 IU per deciliter between weeks 2 and 9 after gene transfer in all seven participants, and the level in six participants increased to a normal value (>50 IU per deciliter) that was maintained at 1 year after receipt of the dose. In the high-dose cohort, the median annualized bleeding rate among participants who had previously received prophylactic therapy decreased from 16 events before the study to 1 event after gene transfer, and factor VIII use for participant-reported bleeding ceased in all the participants in this cohort by week 22. The primary adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper limit of the normal range or less. Progression of preexisting chronic arthropathy in one participant was the only serious adverse event. No neutralizing antibodies to factor VIII were detected. CONCLUSIONS: The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stabilization of hemostasis and a profound reduction in factor VIII use in all seven participants. In this small study, no safety events were noted, but no safety conclusions can be drawn. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795 ; EudraCT number, 2014-003880-38 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both transgene products, FVIII-SQ and FIX-R338L, demonstrate variable activity measurements in OSA versus chromogenic assay (CSA) determinants of factor activity that are reproducible across trials.144,145,149,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [28]
In the citing paper
“clinical gene therapy using a codon-optimized exogenous construct to compensate for mutations in a nuclear gene (e.g. hemophilia, [69]) is ongoing”
From Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinás, A. M., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,949
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H. Z., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 682
Flagged first, then by citations
Research works printed but not linked: 1
- Falese L, Gene Ther
Cited by
Sorted by citations
Items 601–692 of 692
Cohn, C. S., Allen, E. S., Cushing, M. M., Dunbar, N. M., Friedman, D. F., Goel, R., Harm, S. K., Heddle, N. M., Hopkins, C. K., Klapper, E. B., et al. (2019) · Transfusion · doi:10.1111/trf.15348 · Cited by 1
Zhukouskaya, V. V., Jauze, L., Charles, S., Leborgne, C., Hilliquin, S., Sadoine, J., Slimani, L., Baroukh, B., van Wittenberghe, L., Danièle, N., et al. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.14.14 · Cited by 1
Gene Therapy in Hemophilia: From Hype to Hope
Schutgens, R. E. G. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000037 · Cited by 1
Non-replacement therapy for haemophilia treatment: fetching the east by the west.
Marietta, M., & Luppi, M. (2018) · Blood transfusion · doi:10.2450/2018.0032-18 · Cited by 1
Rive, C. M., Yung, E., Dreolini, L., Brown, S. D., May, C. G., Woodsworth, D. J., & Holt, R. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.098335 · Cited by 1
Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integrationPreprint
Li, D., Chen, X., Niu, X., Liu, Y., Zheng, R., Wang, L., Yang, L., Lu, J., Yin, S., Shao, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-302699/v1 · Cited by 1
Biomarker and Bioanalytical Readouts for the Development of AAV Gene Therapy
Lu, Y., & Lembke, W. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch3 · Cited by 1
Bioanalytical Methods to Study Biodistribution and Shedding of AAV ‐Based Gene Therapy Vectors
Vettermann, C., & Soon, R. K. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch7 · Cited by 1
Self-citationFactoring in new gene therapy treatments for hemophilia A
Byrne, L. C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7511
Achievements in 2017, Promises of 2018
Verma, I. C. (2018) · Journal of Fetal Medicine · doi:10.1007/s40556-018-0164-4
General Management of Hemophilia
Green, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812954-8.00007-2
Gene and Cell Therapy: Tearing Down Walls
VandenDriessche, T. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.29074.tva
Emerging human protoparvoviruses : in search of acute infections
Jokinen, M. (2019) · Työväentutkimus Vuosikirja
Gene Therapy: Principles and Clinical Potential
Buckley, S. M. K., & David, A. L. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108564434.053
THE DEVELOPMENT of a SAFE and OPTIMIZED GENE THERAPY for HUMAN DISEASES
Supit, A. S. A., & Tompodung, L. M. (2019) · JURNAL BIOSAINS · doi:10.24114/jbio.v5i3.12472
Waramit, S., Suwan, K., Asavarut, P., Ashfield, R., Draper, S., & Hajitou, A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.29087.abstracts
Microparticles in hemophilia - friend or foe? : to improve hemostasis or to induce atherothrombosis?
Zong, Y. (2020) · Figshare
Layer, R. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00035-0
In UteroStem Cell Transplantation, Enzyme Replacement, and Gene Therapy
MacKenzie, T. C., & Schwab, M. E. (2021) · Wiley eBooks · doi:10.1002/9781119676980.ch30
Haematology in the UK: A 60‐year personal perspective
Hoffbrand, A. V. (2021) · eJHaem · doi:10.1002/jha2.213
Development, market authorization and market access of gene and cell-based therapies
ten Ham, R. M. T. (2021) · doi:10.33540/612
Characterizing early blood-induced joint damage
Pulles, A. E. (2021) · doi:10.33540/881
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Positioning of non-factor replacement therapy in the hemophilia treatment
Sakai, M. (2022) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.33.37
Chen, S., & Cass, A. S. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.hemophilia_overview
Conboy, I. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733450908.793553930
大森, 司. (2018) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.29.760
Gene Therapy in Haemophilia: Updates from Clinical Trials and Insights to Future Technologies
Carter, S. (2022) · EMJ Cardiology · doi:10.33590/emjcardiol/10136425
Gene and Cell Therapy: How to Build a BioDrug
Baumeister, S. H. C., & Woolfrey, A. E. (2022) · Pediatric oncology · doi:10.1007/978-3-031-06357-2_6
Development of in vitro gene editing therapy in disease treatment
Han, Y., Wenbin, S., Yan, Y., & Zhao, J. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5651
Kwiatek, M., Michalski, A., Abramowicz, K., Rutyna, P., Wasiak, M., Reichert, M., & Lisowski, L. (2023) · Lekarz Wojskowy · doi:10.53301/lw/156374
Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders
Rader, D. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00030-3
Genome Integration of Adeno-associated Virus (AAV) Vectors into Infected Cells
Hirai, Y. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.211
Breakthrough Study Develops Potential Cure for Hemophilia A
Cole, E. (2023) · Qapsule Queen s Undergraduate Health Sciences Journal · doi:10.24908/qap.v1i1.16374
Braun, M., & Sun, K. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch4
Strategies to target and genetically modify the liver sinusoid
Westwood, L. J., Couteur, D. G. L., Hunt, N. J., & Cogger, V. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00008-5
Disease Models for Rare Genetic Disorders
Kanakarajan, S., Selvaraj, R., & Kaleena, P. K. (2024) · Springer eBooks · doi:10.1007/978-981-99-9323-9_4
Un nouvel espoir dans le traitement de l’hémophilie A
Vaidie, J., & Silvain, A. R. (2024) · médecine/sciences · doi:10.1051/medsci/2024048
Fleischmann, T. T. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2418961
PROCESO DE ATENCIÓN DE ENFERMERÍA EN UN PACIENTE CON HEMOFILIA TIPO A - REPORTE DE CASO CLÍNICO
Pacheco, M. A. S., Ortiz, M. A. M., Salto, J. E. T., Baculima, D. T. R., & Durazno, D. V. O. (2024) · RECISATEC - REVISTA CIENTÍFICA SAÚDE E TECNOLOGIA · doi:10.70187/recisatec.v4i2.371
Even a Worm Will Turn: Immunity Following AAV Vector Administration
Patel, K., Khatri, A., & Somanathan, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_7
Genetic Characterization of the Factor VIII Gene
Villadiego, A. M., & Doncel, S. S. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009259
Samelson‐Jones, B. J. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102716
The bleeding edge: broadening horizons for hematopoietic stem cell therapies
Shelton, S. D., & Sankaran, V. G. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.003
Gene Therapy: The New Frontier in Haemophilia Treatment
(2025) · EMJ Hematology · doi:10.33590/emjhematol/xcxc9930
A packaging-regulated adenoviral vector for rAAV production
Lu, D., Li, R., Liang, Q., Xiao, Z., & Liu, Q. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152326
A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy
Pasha, S. F. A., Anver, T. F. K., & Srinivasamurthy, S. K. (2025) · Current Gene Therapy · doi:10.2174/0115665232389378250727013548
Nonsurgical Control of Seizure Threshold with Acoustically Targeted Chemogenetics
Li, H., Nouraein, S., Lee, S., Link, S. S., Raisley, E. K., & Szablowski, J. O. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00404
Platelet-Mediated Gene and Cell Therapy
Miao, C. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_18
Xu, B., Zhang, X., Yu, D., Wang, P., Chi, Y., Liu, W., Xue, F., Chen, L., Li, H., Wang, W., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201832
Chauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Figshare · doi:10.6084/m9.figshare.26952309
Gong, J., Yang, R., Zhou, M., & Chang, L.-J. (2023) · Figshare · doi:10.6084/m9.figshare.23504967
Fletcher, S., Jenner, K., Pembroke, L., Holland, M., & Khair, K. (2022) · Figshare · doi:10.6084/m9.figshare.19517413
Deng, M., Zhou, H., He, S., Qiu, H., Wang, Y., Zhao, A. Y., Mu, Y., Li, F., & Zhao, A. Z. (2023) · Figshare · doi:10.6084/m9.figshare.24091765
Fletcher, S. J., Jenner, K., Pembroke, L., Holland, M., & Khair, K. (2022) · Figshare · doi:10.6084/m9.figshare.19517410
Fletcher, S., Jenner, K., Holland, M., & Khair, K. (2024) · Figshare · doi:10.6084/m9.figshare.26679566
Gong, J., Yang, R., Zhou, M., & Chang, L.-J. (2023) · Figshare · doi:10.6084/m9.figshare.23504970
Shi, B., Olivares, P., Parunov, L. A., Liang, Y., Chun, H., Wu, W. W., Simhadri, V. L., Bajgain, P., Jankowski, W., Krivega, M., et al. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.103325
Genetik menschlicher Erkrankungen
Ehrenhofer‐Murray, A. E. (2025) · Springer eBooks · doi:10.1007/978-3-662-70328-1_13
Characterization of adeno-associated virus binding to alginate and its controlled release
Amante, J. J., Mandeville, J. R., Hargrove, H., Zhang, X. F., & Kearney, C. J. (2026) · Nanoscale Advances · doi:10.1039/d5na00713e
Hemophilia B gene therapy: a NAb–solute barrier overcome by adeno-associated virus serotype 5
Kaczmarek, R. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.103428
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
Raheja, P., Rangarajan, S., Lester, W., Madan, B., Pierce, G. F., Symington, E. M., Millar, C. M., Osmond, D., Li, M., & Chavele, K.-M. (2026) · Haemophilia · doi:10.1111/hae.70284
Self-citationHemophilia A gene therapy: Moving to the next chapter
Kaczmarek, R., Herzog, R. W., & Skinner, M. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.006
ГЕМОФІЛІЯ В ДОРОСЛОМУ ВІЦІ: УПРАВЛІННЯ РИЗИКАМИ КРОВОТЕЧ ТА СУЧАСНІ СТАНДАРТИ ЗАМІСНОЇ ТЕРАПІЇ
Мандрик, О., Бойку, А. Л., Яворська, В., & Москаль, В. (2026) · ГРААЛЬ НАУКИ · doi:10.36074/grail-of-science.03.04.2026.091
La thérapie génique dans l’hémophilie
Rauch, A. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.02.012
L’hémophilie et l’évolution de sa prise en charge
Daniel, M., & Susen, S. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.02.011
稲葉, 浩. (2024) · Institutional Repositories DataBase (IRDB)
Ramamurthy, R. M., Zheng, W. T., Wachtman, S. E., Diaz, J. H., George, S. K., Simon, T., Zhou, Y., Wan, M., Lu, B., Walker, S. J., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201772
Siddiqui, S., Parab, S. B., & Bhatt, L. K. (2026) · Biotechnology Journal · doi:10.1002/biot.70262
Vicidomini, A., Boisgérault, F., Romano, G., Guarnaccia, C., Vidal, P., Collaud, F., Soria, L. R., Sabbata, G. D., Tedesco, N., Lisjak, M., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201793
Yin, L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016169
Beyond innovation: why rare disease gene therapy needs a reset
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2706035
CRISTOFARO, R. D. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.05.002
An ER stress-responsive RNA rheostat for programmable gene and mRNA therapies
Ogurlu, R., Sanchez, E. B., Hull, J. A., Fergione, S., Yudistyra, V., Webb, G. M., Wu, H. L., Pessoa, C. T., Humkey, M. C., Potter, S. K., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.07.006
Five-year durability in cell and gene therapy: evidence review and implications for payer coverage
Pittos, E. C., & DePinto, J. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2026.2723931
Gene Therapy Approaches for the Treatment of Phenylketonuria
Martinez, M. A., Young, L. J., Harding, C. O., Schwank, G., & Thöny, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-26690-3_20
Clinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848
In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies
Li, Y., Wang, F., Li, J., Gao, H., Li, D., & Wang, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118491
Wang, Z., Wu, N., Fu, D., Zhao, Q., & Wang, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-71872-w
Fletcher, S. J., Jenner, K., & Khair, K. (2026) · Bleeding Disorders Care & Practice · doi:10.17225/bdcp-2026-0006
Shaik, M. Y., Patel, J., Kakadia, S., & Divers, S. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70348
Metadata
- Authors
- Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., & Pasi, K. J.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-28
- Volume
- 377
- Issue
- 26
- Pages
- 2519-2530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2775538622
- Cited by
- 694
- References
- 29
- Citations by year
- 2026: 33 · 2025: 59 · 2024: 65 · 2023: 57 · 2022: 95 · 2021: 81 · 2020: 112 · 2019: 90 · 2018: 95 · 2017: 5
- FWCI
- 63.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- University Hospitals Birmingham NHS Foundation Trust
- National Institute for Health and Care Research
- University of Cambridge
- Imperial College London
- Imperial College Healthcare NHS Trust
- Barts Health NHS Trust
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, gene therapy, factor VIII, B-domain-deleted factor VIII, codon optimization, annualized bleeding rate, factor VIII activity, dose escalation, alanine aminotransferase elevation, chronic arthropathy, neutralizing antibodies
- MeSH terms
- Dependovirus, Adult, Antibodies, Viral, DNA, Viral, Factor VIII, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Genetic Therapy, Virus Shedding, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
